Daiichi Sankyo and partner AstraZeneca’s Enhertu previously wowed industry watchers with stellar clinical data in heavily pretreated breast cancer, leading to a speedy FDA nod at the end of 2019.

Looking good there, too (and watch out for data to come out of ASCO 2023 just next week ... there wouldn't surprise anyone). Daiichi Sankyo is a strong pharma company that does not get nearly ...